Lactobacillus murinus and Arginine: A Novel Strategy Against Fructose-Induced MASLD

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a growing global health concern, often exacerbated by high dietary fructose intake. A recent study published in Food Science & Nutrition explored the potential of Lactobacillus murinus (L. murinus) to counteract the effects of high-fructose diets on MASLD progression, identifying a novel mechanism involving arginine metabolism.

The Study in Detail

The study, conducted by Mo X. et al. and published in Food Science & Nutrition (2026 Feb 17;14(2):e71502), investigated the impact of fructose supplementation on MASLD progression in wild-type C57BL/6 mice. The researchers utilized both high-fructose drinking water and a high-fructose diet to induce MASLD. Through 16S rDNA sequencing, they observed that long-term fructose exposure significantly reduced the abundance of L. murinus in the intestines of the mice.

To further elucidate the role of L. murinus, the team exogenously supplemented L. murinus in the high-fructose mouse model. This intervention significantly alleviated fructose-induced MASLD symptoms, characterized by:

• Reduced liver ballooning and inflammation
• Decreased hepatic cholesterol and triglycerides
• Lower blood cholesterol, triglycerides, ALT, and AST levels

To uncover the mechanistic basis of this protection, serum and fecal metabolomic analyses were performed. These analyses identified arginine as the sole metabolite that exhibited marked reductions in both serum and intestinal compartments in fructose-fed mice. Integrated multi-omics analysis revealed a strong positive correlation between gut L. murinus abundance and arginine levels. ELISA confirmed that exogenous administration of L. murinus effectively restored circulating arginine concentrations in high-fructose-fed mice.

Importantly, direct arginine supplementation produced similar therapeutic benefits as L. murinus, improving key features of MASLD, including reduced liver ballooning, less liver inflammation, lower buildup of cholesterol and triglycerides in the liver and blood, and decreased ALT/AST levels.

Assessment

This study provides compelling evidence for a novel mechanism underlying fructose-induced MASLD: the reduction of gut L. murinus abundance, which subsequently disrupts arginine metabolism. The findings suggest that L. murinus plays a critical protective role against fructose-induced liver damage. The identification of arginine as a key mediator is a significant breakthrough, as it offers a clear metabolic pathway through which L. murinus exerts its beneficial effects.

Strengths: The study employs a robust animal model, utilizes multi-omics approaches (16S rDNA sequencing, metabolomics), and includes a direct intervention with both the probiotic and the identified metabolite (arginine), strengthening the causal link. The detailed characterization of MASLD symptoms provides comprehensive support for the observed improvements.

Limitations: As an animal study, the direct translatability to human physiology requires further investigation. While the study identifies a strong correlation and therapeutic effect, the precise molecular mechanisms by which L. murinus boosts arginine production or how reduced arginine directly contributes to MASLD progression warrant deeper exploration.

Practical Relevance

The results of this research hold significant practical implications for nutrition and health, particularly in the context of high-fructose diets. Given the widespread consumption of fructose in processed foods and beverages, strategies to mitigate its adverse effects on liver health are crucial.

• Dietary Considerations: The study reinforces the importance of moderating fructose intake to prevent the disruption of gut microbiota and subsequent metabolic issues like MASLD.
• Probiotic Potential: L. murinus could emerge as a promising probiotic supplement for individuals at risk of or suffering from fructose-induced MASLD. Incorporating foods rich in beneficial lactobacilli or specific probiotic formulations might be a preventive or therapeutic strategy.
• Arginine Supplementation: The finding that arginine supplementation alone mimics the benefits of L. murinus suggests that dietary or supplemental arginine could be a targeted intervention. Arginine is an amino acid found in protein-rich foods like meat, poultry, fish, nuts, and dairy.
• Personalized Nutrition: Future research may lead to personalized nutritional strategies, where gut microbiome analysis could identify individuals with reduced L. murinus levels, guiding interventions with specific probiotics or arginine.

Conclusion

This study reveals a critical link between high dietary fructose, reduced gut Lactobacillus murinus, disrupted arginine metabolism, and the development of MASLD. The findings suggest that both L. murinus and arginine supplementation could serve as potential therapeutic strategies against fructose-induced MASLD. Further human studies are needed to confirm these promising results and translate them into clinical practice.